

10. Studer UE, Collette L, Whelan P et al.: Using PSA to guide timing of androgen deprivation in patients with T0-4 NO-2 MO prostate cancer not suitable for local curative treatment (EORTC 30891). *Eur Urol* 2008; 53: 941–9.
11. Mohler JL, Williams BT, Freeman JA: Expectant management as an option for men with stage T1c prostate cancer: a preliminary study. *World J Urol* 1997; 15: 364–8.
12. Choo R, Klotz L, Danjoux C et al.: Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. *J Urol* 2002; 167: 1664–9.
13. Chen WM, Yang CR, Ou YC et al.: Clinical outcome of patients with stage T1a prostate cancer. *J Chin Med Assoc* 2003; 66: 236–40.
14. Khan MA, Carter HB, Epstein JI et al.: Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? *J Urol* 2003; 170: 2274–78.
15. Patel MI, DeConcini DT, Lopez-Corona E, Ohori M, Wheeler T, Scardino PT: An analysis of men with clinically localized prostate cancer who deferred definitive therapy. *J Urol* 2004; 171: 1520–4.
16. Martin RM, Gunnell D, Hamdy F, Neal D, Lane A, Donovan J: Continuing controversy over monitoring men with localized prostate cancer: a systematic review on programs in the prostate specific antigen era. *J Urol* 2006; 176: 439–49.
17. Klotz L: Active Surveillance for prostate cancer: for whom? *J Clin Oncol* 2005; 23: 8165–9.
18. American Urological Association: Guideline prostate cancer. www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm
19. National Institute for Health and Clinical Excellence: Prostate cancer. www.nice.org.uk/guidance/index.jsp?action=byID&o=11924
20. D'Amico AV, Whittington R, Malkowicz SB et al.: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. *JAMA* 1998; 280: 969–74.
21. Epstein JI, Chan DW, Sokoll LJ et al.: Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. *J Urol* 1998; 160: 2407–11.
22. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR: Contemporary trends in low risk prostate cancer: risk assessment and treatment. *J Urol* 2007; 178: S14–19
23. Kattan MW, Eastham JA, Wheeler TM et al.: Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors. *J Urol* 2003; 170: 1792–7.
24. Cooperberg MR, Broering JM, Litwin MS et al.: The contemporary management of prostate cancer in the United States: Lessons from the Cancer of the Prostate Urologic Strategic Research Endeavour (CaPSURE), a National Disease Registry. *J Urol* 2004; 171: 1393–401.
25. Warlick C, Trock BJ, Landis P, Epstein JI, Carter HB: Delayed versus immediate surgical intervention and prostate cancer outcome. *J Natl Cancer Inst* 2006; 98: 355–7.

Corresponding author
 Prof. Dr. med. Lothar Weißbach
 Privatärztliche Urologische Gemeinschaftspraxis
 in der EuromedClinic Fürth
 Europa-Allee 1
 90763 Fürth, Germany
lothar.weissbach@euromed.de

 For e-references please refer to:
www.aerzteblatt-international.de/ref2209

Erratum

In the original article "**Cowpox Virus Infection in Pet Rat Owners—Not Always Immediately Recognized**" by Becker et al. (*Dtsch Arztebl Int* 2009; 106(19): 329-34) two sentences were incorrect:

In the chapter entitled "Case 2" on page 330, the last sentence of the first paragraph should read: "A bacteriological wound swab remained sterile."

In the last chapter ("Discussion"), the second sentence of the next-to-last paragraph on page 333 should read: "Investigations in the 3 pet shops that were implicated in the first 4 cases did not confirm with absolute certainty the presumed epidemiological association."